Navigation Links
Arena Pharmaceuticals Announces Initiation of Phase 1 Clinical Trial of Type 2 Diabetes Drug Candidate in Partnership with Ortho-McNeil-Janssen Pharmaceuticals
Date:12/15/2008

inal tract, and in preclinical studies the GDIR stimulates the release of GLP and GIP, two incretins that play an important role in insulin regulation and glucose homeostasis. GDIR stimulation has also been found to increase the levels and activity of intracellular factors thought to be involved in the preservation of beta cells, and GDIR signaling may therefore also serve to maintain beta cell mass in type 2 diabetes.

About Diabetes

Diabetes is a major worldwide disease. The International Diabetes Federation estimates that in 2007 there were 246 million adults with diabetes worldwide, an increase of over 20% since 2003. Approximately 90%, or 221 million, of diabetics worldwide suffer from type 2 diabetes, the adult-onset form of the disease. Type 2 diabetes is characterized by inadequate response to insulin or inadequate secretion of insulin as blood glucose levels rise. Therapies for type 2 diabetes are directed toward correcting the body's inadequate response with oral or injectable medications, or directly modifying insulin levels by injection of insulin or insulin analogs.

The worldwide market for diabetes medications exceeded $12 billion in 2005, of which oral drugs exceeded $7 billion. Current oral medications for type 2 diabetes have limitations including side effects and safety issues prompting continued efforts to develop therapeutics to improve the treatment of diabetes.

About Arena Pharmaceuticals

Arena is a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing oral drugs in four major therapeutic areas: cardiovascular, central nervous system, inflammatory and metabolic diseases. Arena's most advanced drug candidate, lorcaserin, is being investigated in a Phase 3 clinical trial program for the treatment of obesity. Arena's broad pipeline of novel compounds target G protein-coupled receptors, an important class of v
'/>"/>

SOURCE Arena Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Arena Pharmaceuticals to Present at Four Upcoming Investor Conferences
2. Arena Pharmaceuticals Announces Positive Phase 2 Clinical Trial Results of APD125 for the Treatment of Insomnia
3. Arena Pharmaceuticals Announces APD668 Initial Clinical Study Results Suggest Glucose-Dependent Insulinotropic Receptors May Improve Glucose Control in Patients With Type 2 Diabetes
4. Arena Pharmaceuticals Announces Positive Phase 1a Clinical Trial Results of APD791 for the Treatment of Arterial Thrombosis and Initiates Phase 1b Clinical Trial
5. Arena Pharmaceuticals Initiates Phase 2b Clinical Trial of APD125 for the Treatment of Insomnia
6. Arena Pharmaceuticals, Inc. Announces Initiation of Phase 1 Clinical Trial of Drug Candidate Under Partnership with Taisho Pharmaceutical Co., Ltd.
7. Arena Pharmaceuticals Presented Positive Phase 2a Clinical Trial Results of APD125 for the Treatment of Insomnia at 22nd Annual Meeting of the Associated Professional Sleep Societies
8. Arena Pharmaceuticals Announces Positive Phase 1b Clinical Trial Results of APD791 for the Treatment of Arterial Thrombosis
9. Critical Pharmaceuticals Enter Sustained Release hGH Arena
10. Arena Pharmaceuticals Announces Preliminary Results of Phase 2b Clinical Trial of APD125 for the Treatment of Insomnia
11. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2014)... , Aug. 27, 2014 /PRNewswire-iReach/ -- In a ... bridge the gap between the electronic medical record ... links, readers can experience, first-hand, how seamless integration ... Photo - http://photos.prnewswire.com/prnh/20140827/140443 ... access to imaging from within the patient record ...
(Date:8/27/2014)... CITY , Aug. 27, 2014 Varian Medical ... expand its current Salt Lake City ... underway outside of Utah to ultimately ... the next 20 years. " Utah ... and technical talent, many of whom can be credited with ...
(Date:8/27/2014)... Aug. 27, 2014 By now, if you haven,t ... living on this planet. The awareness campaign has brought this ... helped to raise over $88.5 Million (and counting) for ALS. ... some companies are starting to as well. One ... Florida , who actually works with ALS sufferers and ...
Breaking Medicine Technology:DICOM Grid Launches Interactive Guide to Demonstrate Image-Enabling the EMR 2Varian Medical Systems Groundbreaking on Facility Expansion Triggers Influx of New Jobs to Salt Lake 2Varian Medical Systems Groundbreaking on Facility Expansion Triggers Influx of New Jobs to Salt Lake 3Varian Medical Systems Groundbreaking on Facility Expansion Triggers Influx of New Jobs to Salt Lake 4Acorn Stairlifts Gives a Lift to the ALS Ice Bucket Challenge 2
... Pa., Sept. 18 ,Interleukin Genetics, Inc. (Amex: ... research collaboration to explore the role of genetics ... develop a series of genetic,tests that will help ... loss and, more specifically, gauge a patient,s,likelihood of ...
... Assess Effectiveness of Cladribine Tablets, in Preventing Conversion to Definite Multiple Sclerosis in Addition ... Fully Enrolled Phase III Pivotal Trial - ... - the CLARITY Study - ... GENEVA, Sept. 18 Merck Serono, a division of Merck,KGaA, Darmstadt, Germany, announced today ...
Cached Medicine Technology:Interleukin Genetics and Geisinger to Collaborate on Genetic Tests to Predict Weight Loss Success 2Interleukin Genetics and Geisinger to Collaborate on Genetic Tests to Predict Weight Loss Success 3Merck Serono Announces Initiation of the ORACLE MS Trial to Evaluate Cladribine Tablets in Patients at Risk of Developing Multiple Sclerosis 2Merck Serono Announces Initiation of the ORACLE MS Trial to Evaluate Cladribine Tablets in Patients at Risk of Developing Multiple Sclerosis 3Merck Serono Announces Initiation of the ORACLE MS Trial to Evaluate Cladribine Tablets in Patients at Risk of Developing Multiple Sclerosis 4Merck Serono Announces Initiation of the ORACLE MS Trial to Evaluate Cladribine Tablets in Patients at Risk of Developing Multiple Sclerosis 5
(Date:8/28/2014)... August 28, 2014 Coveros, Inc., ... announced that it has partnered with InfoZen on ... performance start date of 2/4/2014 with U.S. Citizenship ... Security (DHS) agency that oversees lawful immigration to ... and InfoZen will automate the integration and delivery ...
(Date:8/28/2014)... UniVoIP, Inc, a managed telephony ... announced that they have been certified with the state ... Small Business Enterprise (Local SBE) Preference Programs. “We are ... state of California and LA county and excited to ... to governmental agencies throughout the state,“ says Chris ...
(Date:8/27/2014)... 2014 A St. Louis law firm ... reports that the C.R. Bard multidistrict litigation (MDL), ... transvaginal mesh lawsuits, recently filed a new pretrial order ... the pretrial discovery process, and more specifically to the ... Carey Danis & Lowe is a law firm practicing ...
(Date:8/27/2014)... Recently, BambooIndustry.com, an innovative company that provides many kinds ... bamboo panels are now offered on its website. In ... worldwide. All people that place an order for its newly ... 30 percent off. , The company’s senior spokesman was ... all our new and old customers can buy cheap bamboo ...
(Date:8/27/2014)... August 28, 2014 Women’s Prosperity Network ... of As Seen On TV, Inc., and NY Times ... Maker”. as Excelerate attendees will learn how to pitch ... the ability to pitch to an investor panel. , ... Experts and Millionaire Mentors directly to attendees. , ...
Breaking Medicine News(10 mins):Health News:Coveros Partners with InfoZen on USCIS Transformation Integration Award 2Health News:Cloud PBX Provider UniVoIP Gets Certified by the State of California and the County of Los Angeles Under the Local Small Business Enterprise (SBE) Preference Program 2Health News:Carey Danis & Lowe Reports On New Court Order in C.R. Bard Transvaginal Mesh MDL 2Health News:BambooIndustry.com: Cheap Bamboo Panels for Clients Worldwide Offered Online 2
... Staffing Software introduces new features that quicken the recruitment process by ... across the web. , ... High Point, NC (Vocus) ... announced its first independently developed app called Capture Healthcare Job ...
... and Translation Firm Maintains WBENC Certification. , ... ... LLE®, a leading provider of foreign language interpretation, translation and ... the world, has received its renewed certification as a Women’s ...
... version 2.0 service: an innovative medical news search engine and ... medical sources is found. Excellent new tool for medical specialists, doctors ... ... 23, 2009 -- Newsguard today launched its rebranded version 2.0 service: ...
... England, April 23 We are all living,in stressful, uncertain times, but it ... stress and that is to produce stress hormones. This,is true whether: , , ... man with an axe, - You owe the bank GBP750,000 ... about to go out in front of an audience of, ...
... ON HEALTH REFORM, INCLUDING PUBLIC PLAN AND SOME TAX ... Will Hinge on Actual DebateMENLO PARK, Calif., April 23 ... the public continues to say that they or a ... care in the past year, according to the Kaiser ...
... for EvistaINDIANAPOLIS, April 22 Eli Lilly and Company ... District Court for the Southern District of Indiana today ... a generic version of Lilly,s medicine Evista(R) (raloxifene HCl ... final ruling. Teva had indicated it was prepared to ...
Cached Medicine News:Health News:BlueSky Medical Staffing Software Launches First Job Aggregation Engine App and Releases API for Developers 2Health News:BlueSky Medical Staffing Software Launches First Job Aggregation Engine App and Releases API for Developers 3Health News:LLE Receives Renewal of Women's Business Enterprise National Council Certification 2Health News:Innovative Search Engine for Medical News, Newsguard 2.0, Launched 2Health News:Stress and its Remedies 2Health News:Stress and its Remedies 3Health News:Six in Ten Say Family Put Off Medical Care Due to Cost 2Health News:Six in Ten Say Family Put Off Medical Care Due to Cost 3Health News:Six in Ten Say Family Put Off Medical Care Due to Cost 4Health News:Six in Ten Say Family Put Off Medical Care Due to Cost 5Health News:Six in Ten Say Family Put Off Medical Care Due to Cost 6Health News:Lilly Granted Preliminary Injunction to Prevent Launch of Generic Raloxifene 2Health News:Lilly Granted Preliminary Injunction to Prevent Launch of Generic Raloxifene 3
Black multi-pinhole occluder...
9 inch double ended with one end black and the other end with 49 holes...
Double Ended Occluders...
49 pinholes, black...
Medicine Products: